zografos anti veg fs in ocular oncology
DESCRIPTION
http://www.tvrs.gr/TRANSCRIPT
![Page 1: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/1.jpg)
Leonidas ZografosLausanne
Anti-VEGFs in Ocular Oncology
4th Thessaloniki International Vitreo-Retinal Summer School, 16-21. 6.2014, Electra Palace
![Page 2: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/2.jpg)
Intravitreal anti-VEGF in ocular oncology
• Impact in the progression of uveal melanomas• Treatment of choroidal metastasis• Treatment of vascular and pediatric tumors• Treatment on CNV associated to
- choroidal nevi- choroidal osteomas
• Treatment and prevention of irradiation induced complications- Treatment of irradiation induced optic neuropathy- Treatment of retinopathy and maculopathy- Treatment of neovascular glaucoma- Prevention of neovascular glaucoma- Treatment of secondary retinal detachment
![Page 3: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/3.jpg)
Choroidal metastasesAnti-VEGF treatment
N. of publications 10
N. of cases 11
Systemic
chemotherapy 5 / 11 c.
Obs. period 1 – 6 m.
Local tumor control 11 / 11 c.
![Page 4: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/4.jpg)
F. 44 y.Breast cancer + metastasesVis. Ac. 1.0
1 IV Avastin
![Page 5: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/5.jpg)
4.2013 Vis. Ac. 1.0 6.2013 Vis. Ac. 1.0
![Page 6: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/6.jpg)
Treatment of vascular and pediatric tumorsCoat’s deseases
Courtesy F. Munier, MD
![Page 7: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/7.jpg)
Ranibizumab 2 iv inj.
Treatment of vascular and pediatric tumorsCoat’s deseases
![Page 8: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/8.jpg)
Intravitreal anti-VEGF in ocular oncology
• Impact in the progression of uveal melanomas• Treatment of choroidal metastasis• Treatment of vascular and pediatric tumors• Treatment on CNV associated to
- choroidal nevi- choroidal osteomas
• Treatment and prevention of irradiation induced complications- Treatment of irradiation induced optic neuropathy- Treatment of retinopathy and maculopathy- Treatment of neovascular glaucoma- Prevention of neovascular glaucoma- Treatment of secondary retinal detachment
![Page 9: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/9.jpg)
Choroidal nevus + CNVLaser treatment
Vis. Ac. 0.3
![Page 10: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/10.jpg)
Choroidal nevus + CNVLaser treatment
Vis. Ac. 1.0
![Page 11: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/11.jpg)
Ac. Vis. 0.5
Naevus + CNV
Période d’obs. 12 mois9 inj. Avastin
![Page 12: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/12.jpg)
Ac. Vis. 0.2 Trithérapie Ac. Vis. 0.3
![Page 13: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/13.jpg)
Intravitreal anti-VEGF in ocular oncology
• Impact in the progression of uveal melanomas• Treatment of choroidal metastasis• Treatment of vascular and pediatric tumors• Treatment on CNV associated to
- choroidal nevi- choroidal osteomas
• Treatment and prevention of irradiation induced complications- Treatment of irradiation induced optic neuropathy- Treatment of retinopathy and maculopathy- Treatment of neovascular glaucoma- Prevention of neovascular glaucoma- Treatment of secondary retinal detachment
![Page 14: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/14.jpg)
Observation period 3 years
Distance tumor – optic disc 2.7 mm
Uveal melanoma proton beam radiotherapy
![Page 15: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/15.jpg)
Irradiation inducedOptic Neuropathy
Uveal melanoma proton beam radiotherapy
![Page 16: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/16.jpg)
Obs. period. 2 years / 3 years
Radiation retinopathy
![Page 17: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/17.jpg)
Irradiation induced maculopathy
Radiation retinopathy
![Page 18: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/18.jpg)
External beam radiation Dose 30Gy
Vis. Ac. = 0.3 Avastin 3x
![Page 19: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/19.jpg)
3 months Vis. Ac. = 0.9
![Page 20: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/20.jpg)
Uveal melanomaProton beam radiotherapyIrrad. Dose 60 Gy
Vis. Ac. = 0.001 Bevacizumab 6x
Irradiation induced maculopathy
![Page 21: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/21.jpg)
Obs. period 18 m Vis. Ac. = 0.001
![Page 22: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/22.jpg)
Intravitreal anti-VEGF in ocular oncology
• Impact in the progression of uveal melanomas• Treatment of choroidal metastasis• Treatment of vascular and pediatric tumors• Treatment on CNV associated to
- choroidal nevi- choroidal osteomas
• Treatment and prevention of irradiation induced complications- Treatment of irradiation induced optic neuropathy- Treatment of retinopathy and maculopathy- Treatment of neovascular glaucoma- Prevention of neovascular glaucoma- Treatment of secondary retinal detachment
![Page 23: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/23.jpg)
Iris neovascularisationanti-VEGF treatment
Number of cases : 69
Delay proton beam irradiation iris neovascularisation :
0,5 - 6 years (Mean 1,9 year)
Medical treatment glaucoma : 42 c. 61%
Visual acuity < 0,1 –55 cases 80%0,1-0,6 – 14 cases 20%
![Page 24: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/24.jpg)
Iris Ischemia
![Page 25: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/25.jpg)
![Page 26: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/26.jpg)
F.A. Classification ofiris neovascularisation
Vascular tortuosityPresent – 62 cases 90%Absent – 7 cases 10%
![Page 27: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/27.jpg)
F.A. Classification ofiris neovascularisation
Iris ischemiaPresent – 44 cases 64%Absent – 25 cases 36%
![Page 28: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/28.jpg)
Pupillary- 18 c. 26%
Sectorial- 11 c. 16%
F.A. Classification of iris neovascularisation
![Page 29: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/29.jpg)
Tufts- 10 c. 15%
Diffuse- 30 c. 43%
F.A. Classification of iris neovascularisation
![Page 30: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/30.jpg)
F.A. Classification of iris neovascularisationDiffusion of the dye
+ 31 cases 45%
++ 38 cases 55%
![Page 31: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/31.jpg)
Number of treatments- 1 injection 14 c. 20%- 2 injections 25 c. 36%- 3 – 6 inj. 30 c. 44%
Laser coagulation 32 c. 46%
Metastatic death 0 c.
Local recurrence 0 c.
Intraocular pressure< 20 mmHg 53 c. 84%24-52 mmHg 10 c. 16%
Iris neovascularisation Anti-VEGF treatment
Observation period :6 months – 3 years 63 cases
Enucleation 3 c. 4%
Glaucoma tube 3 c. 4%
![Page 32: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/32.jpg)
Regression of tortuosity
43/56 cases 77%
Iris neovascularisation – anti-VEGF treatment
![Page 33: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/33.jpg)
Regression of iris neovascularisation
43/63 cases 68%
Iris neovascularisation – anti-VEGF treatment
![Page 34: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/34.jpg)
Reduction of the diffusion of the dye
42/63 cases 67%
Iris neovascularisation – anti-VEGF treatment
![Page 35: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/35.jpg)
Regression of iris neovascularisation
Pupillary 13/18 c. 72%
Sectorial 5/9 c. 55%
Tufts 6/10 c. 60%
Diffuse 17/26 c. 65%
Final Intraocular Pressure < 21 mmHg
Pupillary 17/18 c. 94%
Sectorial 5/9 c. 56%
Tufts 9/10 c. 90%
Diffuse 20/26 c. 77%
![Page 36: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/36.jpg)
Vascular Remodelling 12/38 c. 32%
9.2007 26 mmHg 1.2008 14 mmHg 3.2009 17 mmHg
![Page 37: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/37.jpg)
Vascular maturation > 2.5 years f. up 4/8 cases
6.2007 24 mmHg 8.2010 14 mmHg
![Page 38: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/38.jpg)
Proton beam irradiationNeovascular glaucomaRisk factors
Age 0.1110
LTD 0.0534
Height 0.0000
Dist. disc 0.0000
Dist. macula 0.4201
Iris invasion 0.6238
Exteriorization 0.5143
Hemorrhage 0.1716
Inflamm. ant. ch. 0.3282
Retinal detach. 0.0000
![Page 39: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/39.jpg)
N. Cases: 554 cRetinal ischemia 115 cEnucleation 23 cNo treatm. Meta. 1 cProton beam 91 c
150° F. Angiography
![Page 40: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/40.jpg)
Retinal ischemia
LTD≤ 15mm 13%16-20mm 26%≥ 21mm 26%
![Page 41: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/41.jpg)
Retinal ischemia
Height
≤ 5mm 9%5,1-8mm 15%≥ 8,1mm 33%
![Page 42: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/42.jpg)
Retinal detachment< 1 quadr.
1 quadr. 10%2 quadr. 21%
> 3 quadr. 52%
Retinal ischemia
![Page 43: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/43.jpg)
Retinal ischemia 91c.[ - ] Anti-VEGF 62c.[ +] Anti-VEGF 29c
Anti-VEGF treatment6 months 1 inj/2 m.
1 inj/3 m.Laser coagulation of ischemic retina
Therapeutic protocol
![Page 44: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/44.jpg)
Lost to follow-up 19 c.Death ~ metastases 1 c.Treat. interrupted 1 c.
Neovascular GlaucomaObs. period 2 years 70 cases
F. 58 years
![Page 45: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/45.jpg)
10.2011 H = 6.2 mm
04.2012 H = 5.4 mmPatient refused further treatment
10.2012 H = 4.8 mm
![Page 46: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/46.jpg)
Proton beam irrad. + Anti-VEGF treatment
[ - ] Anti-VEGF 62c.[ +] Anti-VEGF 29c.
P=0.02
![Page 47: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/47.jpg)
05.2011
11.2011
Proton beam +Anti-VEGF
![Page 48: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/48.jpg)
Proton beam +Anti-VEGF
Initial panoramic 150°fluorescein angiography
![Page 49: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/49.jpg)
Proton beam +Anti-VEGF
Observation period 1 year
![Page 50: Zografos anti veg fs in ocular oncology](https://reader036.vdocuments.us/reader036/viewer/2022062514/559252451a28ab17498b45a7/html5/thumbnails/50.jpg)
Conclusions
Intraocular injection of anti-VEGF drugs in selected cases is a promising therapeutic approche for the treatment of irradiation complications following conservative management of uveal melanomas